Reports suggest a decision on whether to deploy military tanker drivers has yet to be taken but 150 will get ready
AstraZeneca has just overtaken Next as the FTSE’s top riser, up 3.1%, after announcing that its newly acquired Alexion division would take full control of the rare diseases specialist Caelum Biosciences in a deal that could be worth up to $500m.
Caelum is developing a monoclonal antibody treatment for AL amyloidosis, a a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that could ultimately be fatal. The drug is in late-stage clinical studies.
Next is the top riser on London’s FTSE 100 index, after the UK fashion chain raised its full-year outlook again on the back of soaring sales, although it also warned over rising prices and staff shortages in the run-up to Christmas.
Its shares went up as much as 4% in early trading to hit a fresh record of £84.08, after the company reported pre-tax profits of £346.7 million for the six months 31 July. Full-price brand sales jumped 62% year-on-year and were 8.8% higher compared with pre-pandemic levels.
Continue reading...from The Guardian https://ift.tt/3iijgaT
No comments:
Post a Comment